Patients with hairy cell leukemia have been treated for up to 24 consecutive months. However, it is believed that direct antiproliferative action against tumor cells, inhibition of virus replication and modulation of the host the biological activities of interferon alfa-2a, recombinant are species-restricted, i. It is not known whether this drug is excreted in human milk.
In healthy people, interferon alfa-2a, recombinant exhibited an elimination half-life of 3. ). At higher doses anxiety, , and irritability were observed more frequently.
Roferon-a (interferon alfa-2a, recombinant) should be used with caution in patients with seizure disorders andor compromised central nervous system function. Any patient developing an autoimmune disorder during treatment should be closely monitored and, if appropriate, treatment should be discontinued. In study dm84-38, patients started roferon-a (interferon alfa-2a, recombinant) at 9 miuday, whereas in study mi400, it was progressively escalated from 3 to 9 miuday over the first month.
There are no publis hed studies on the mutagenic potential of roferon-a (interferon alfa-2a, recombinant). The solution in the syringe should be clear or colorless to light yellow in color. Medicines are sometimes prescribed for purposes other than those listed in a medication guide.
Dose reduction and temporary cessation of therapy were required frequently. Adverse experiences that occurred rarely, and may have been related to underlying disease, included in other investigational studies of roferon-a (interferon alfa-2a, recombinant) the following infrequent adverse events have been reported with the investigational use of roferon-a (interferon alfa-2a, recombinant). Twenty-one patients (28) had a minor remission, 8 (11) remained stable, and none had worsening of disease.
In another study, severe adverse effects including deaths were noted in children with previously untreated, ph-negative, prior to initiation of therapy, tests should be performed to quantitate peripheral blood hemoglobin, platelets, granulocytes and hairy cells and bone marrow hairy cells. Roferon-a (interferon alfa-2a, recombinant) should be used with extreme caution in patients who report a history of depression. Pancreatitis has been observed in patients receiving alpha interferon treatment, including those who developed marked triglyceride elevations. Use a new syringe for the injection and use at a different injection site. In patients diagnosed with pancreatitis, discontinuation of therapy with roferon-a (interferon alfa-2a, recombinant) should be considered.
Roferon-a (interferon alfa-2a, recombinant) is to be used during pregnancy only if the potential benefit to the woman justifies the potential risk to the. Medicines are sometimes prescribed for purposes other than those listed in a medication guide. A sustained response (sr) was defined as normalization of alt both at the end of treatment and at the end of at least 6 months of treatment-free follow-up. Roferon-a (interferon alfa-2a, recombinant) has been studied for its effect on fertility in macaca mulatta (rhesus monkeys). Turn and pull off the bright yellow tamper-resistant seal from needle.
If a patient does not respond within 6 months, treatment should be discontinued. See instructions for disposal of the needle and syringe in the section how should i dispose of materials used to inject roferon-a (interferon alfa-2a, recombinant). Liver metabolism and subsequent biliary excretion are considered minor pathways of elimination for alfa interferons. In the clinical studies, such abnormalities required termination of therapy in less than 1 of patients. Talk to your healthcare provider if you have any concerns about how to use roferon-a (interferon alfa-2a, recombinant).
Most patients who take roferon-a (interferon alfa-2a, recombinant) have flu-like symptoms that usually lessen after the first few weeks of treatment. Headache (44), depression (28), decreased mental status (16), dizziness (11), sleep disturbances (11), paresthesia (8), involuntary movements (7) and visual disturbance (6). Do not inject roferon-a (interferon alfa-2a, recombinant) at that site and discard the syringe. Small amounts of radiolabeled interferon alfa-2a, recombinant appear in the of isolated rat kidneys, suggesting near complete reabsorption of interferon alfa-2a, recombinant catabolites. It is advised that complete blood counts (cbc) be obtained pretreatment and monitored routinely during therapy. Complete blood counts with differential platelet counts and clinical chemistry tests should be performed before initiation of roferon-a (interferon alfa-2a, recombinant) therapy and at appropriate periods during therapy. If you do not hear a click, do not use the needle and do not remove the clear needle shield. Ames tests using six different tester strains, with and without metabolic activation, were performed with roferon-a (interferon alfa-2a, recombinant) up to a concentration of 1920 gplate. Nonpregnant rhesus females treated with roferon-a (interferon alfa-2a, recombinant) at doses of 5 and 25 miukgday have shown irregularities, including prolonged or shortened menstrual periods and erratic bleeding these cycles were considered to be anovulatory on the basis that reduced and luteinizing hormones were not observed. When you are finished, place an alcohol swab over the injection site and press slightly.The recommended dosage of Roferon-A (interferon alfa-2a, recombinant) for the .... stomatitis, tooth disorder, urinary tract infection, weakness in extremities.